{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:25Z","timestamp":1794110725799,"version":"4.8.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.05.020","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:13:32Z","timestamp":1788858812000},"page":"1189-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-1989","authenticated-orcid":false,"given":"Juliane","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bleickardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brudno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-4719","authenticated-orcid":false,"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5084-5220","authenticated-orcid":false,"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Plautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Verdun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.020_bib0002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.020_bib0004","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.020_bib0005","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.020_bib0006","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0007","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/bloodadvances.2021004604","article-title":"Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers","volume":"5","author":"Paczesny","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.jtct.2026.05.020_bib0009","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.020_bib0010","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0011","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.020_bib0012","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.020_bib0013","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0015","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0016","article-title":"Evaluating the prognostic utility of CAR-Hematotox score in predicting CAR T-cell toxicities in children and young adults with R\/R B-acute lymphoblastic leukemia (B-ALL)","volume":"30","author":"Nair","year":"2024","journal-title":"Transp Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0017","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.020_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.020_bib0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.020_bib0021","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0022","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.020_bib0023","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.020_bib0024","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0025","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.05.020_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.020_bib0027","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.020_bib0028","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0029","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.18747","article-title":"Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy","volume":"202","author":"Kitamura","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.020_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2026.05.020_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025032352","article-title":"How I treat HLH-like toxicities following immune effector cell therapy","author":"Johnson","year":"2026","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0033","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.jtct.2026.05.020_bib0034","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood.2024025679","article-title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","volume":"144","author":"Deschenes-Simard","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.020_bib0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"10297","key":"10.1016\/j.jtct.2026.05.020_bib0037","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jtct.2026.05.020_bib0039","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0040","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0041","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0042","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2024-194390","article-title":"Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma","volume":"144","author":"Hansen","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2026.05.020_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.020_bib0044","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(23)01667-1","article-title":"P-049 safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM): real world experience","volume":"23","author":"Sidana","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.020_bib0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0046","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0047","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0048","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0049","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0050","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2023-178743","article-title":"Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 studies of ciltacabtagene autoleucel (Cilta-cel)","volume":"142","author":"Van De Donk","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0051","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0052","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.020_bib0053","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.jtct.2026.05.020_bib0054","article-title":"Immu-45. Reversible parkinsonism after Bcma-directed car T cell administration","volume":"25","author":"Gewirtz","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.020_bib0055","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0056","article-title":"Risk factors for delayed neurotoxicity in patients with relapsed myeloma who received ciltacabtagene autoleucel (cilta-cel)","volume":"31","author":"Lim","year":"2025","journal-title":"Transp Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2026.05.020_bib0057","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment","volume":"145","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.020_bib0058","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14740\/jh2046","article-title":"Ruxolitinib is an effective therapy for ciltacabtagene autoleucel-associated parkinsonism in multiple myeloma","volume":"14","author":"Wirk","year":"2025","journal-title":"J Hematol"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.020_bib0059","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.020_bib0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.020_bib0061","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.020_bib0062","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","volume":"146","author":"Kaulen","year":"2025","journal-title":"Blood"},{"issue":"7903","key":"10.1016\/j.jtct.2026.05.020_bib0063","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0064","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0065","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0066","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2024-203279","article-title":"BMS-986393, a G protein-coupled receptor class C Group 5 Member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with relapsed\/refractory (RR) multiple myeloma (MM) and 1-3 prior regimens: updated phase 1 safety and efficacy results","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0067","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/j.jtct.2025.12.598","article-title":"Immune-effector cell-associated enteritis\/colitis (IEC-EC) after ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM): updated clinicopathologic data and management","volume":"32","author":"Mikkilineni","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0068","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.05.020_bib0069","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S2152-2650(24)01911-6","article-title":"P-008 a rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; insights from a multicenter case series","volume":"24","author":"Bar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib0070","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41591-025-04121-8","article-title":"CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy","volume":"32","author":"Ho","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-025-01319-4","article-title":"Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?","volume":"15","author":"Somay","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0072","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-025-01320-x","article-title":"Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma","volume":"15","author":"Banerjee","year":"2025","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.020_bib0073","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","article-title":"Indolent T-cell lymphoproliferative disease of the gastrointestinal tract","volume":"122","author":"Perry","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.05.020_bib0074","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2024-207885","article-title":"Indolent CD8+ CAR T-cell lymphoma of the gastrointestinal tract after ciltacabtagene autoleucel therapy for relapsed\/refractory multiple myeloma","volume":"144","author":"Hosoya","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.05.020_bib0075","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-Cell lymphoma after Cilta-cel CAR T-Cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0076","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.020_bib0077","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025032347","article-title":"Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea","author":"Blumenberg","year":"2026","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0078","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.2025031423","article-title":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine","volume":"147","author":"Hosoya","year":"2026","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.020_bib0079","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0080","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"24","key":"10.1016\/j.jtct.2026.05.020_bib0081","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.020_bib93","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.020_bib94","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase II trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.jtct.2026.05.020_bib0082","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, Phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib95","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.020_bib0083","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jtct.2026.05.020_bib0084","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"issue":"16","key":"10.1016\/j.jtct.2026.05.020_bib0086","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-Class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, Phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.020_bib0087","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0088","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified t cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.020_bib0089","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.020_bib0090","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.020_bib0091","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.020_bib0092","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:56:23Z","timestamp":1791528983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726003635"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}